Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Experts: Extra Caution Needed after France’s Deadly Drug Trial

By Drug Discovery Trends Editor | March 16, 2016

A group of researchers are calling for additional caution when it comes to testing new drugs in human trials after the deadly case in France where one volunteer died and five others became critically ill due to an experimental painkiller.

An editorial was recently published in the British Journal of Clinical Pharmacology reviewing this incident.

Portuguese pharmaceutical company Bial held a Phase 1 trial in early January. The drug being tested was named BIA 10-2474, a fatty acid amide hydrolase (FAAH) inhibitor that targets the body’s endocannabinoid system.

The scientists had found that the drug candidate had went through safety reviews, but did not raise any alarms in terms of safety because it had already “been tested in non-human primates and medicines with a similar mode of action had also been given previously to people without ill effect,” according to Reuters.

Investigators running the trial felt those factors indicated they didn’t need to perform a cautious approach where the first dose of the inhibitor was given to one participant to gauge the effects before administering the medication to other participants.

Plus, a report in Nature back in January had noted previous clinical trials focusing on FAAH inhibitors had shown these compounds were safe, but most of these experiments demonstrated the drugs are ineffective as potential painkillers.

However, a committee appointed by the French National Agency for Medicines and Health Products Safety determined the administered dosage was 40 times above the necessary threshold needed to block FAAH causing the drug to attack other enzymes in the brain, writes The New Scientist.

Ultimately, the authors of the editorial called for tougher risk assessments and recurrent dosing schedules to prevent the chance of this happening again.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE